[10 min read] Sentinel lymph node biopsy: Where do we stand?

This month’s research article is about sentinel lymph node biopsy (SLNB), and is in the form of a viewpoint from two clinicians at the centre of excellence that is Memorial Sloan Kettering Cancer Center in New York.

While we, as GPs, don’t do SLNB in primary care, and as SLNB is only indicated for (specific) invasive melanoma, it is important that we are across the topic.

I recommend you read the full viewpoint, as it speaks to the complexity of understanding what value SLNB might have, how our understanding of the issues around SLNB is changing, and what new and exciting developments there are in the field.

The conclusion of the paper is beautifully articulate: “(SLNB is) modestly invasive, clearly prognostic, potentially therapeutic, and always controversial…”

The paper is linked here.

Prof David Wilkinson


Learn more about skin cancer with the HealthCert Skin Cancer Certificate Courses.

Skin Cancer Certificate Courses in Australia

Read more from Professor David Wilkinson on recent research:

Leave a Reply

Your email address will not be published.

One comment on “[10 min read] Sentinel lymph node biopsy: Where do we stand?

  1. Thanks David. One of the things I have enjoyed during my career is watching treatments come and go, only to return again with more specific indication. Digoxin was classic. 5 years ago I thought SLNB was on the way out.